FDA panel approves adding peptides to compounding list despite scientist concerns

What happened

The FDA's Pharmacy Compounding Advisory Committee voted to add peptides to the list of substances that compounding pharmacies can prepare. This decision came after hearing public comments and presentations from agency scientists regarding specific peptides, including BPC-157, KPV, TB-500, and MOTS-c.

Why it matters

This decision may impact the availability and regulation of compounded medications for patients.

Who feels this

If you are a patient

This decision could affect your access to compounded medications that contain peptides, which may be used for various health conditions. If your doctor prescribes a peptide-based treatment, it may become more readily available through compounding pharmacies.

If you are a small business owner

If you operate a compounding pharmacy, this decision may allow you to expand your offerings by including peptide medications. This could potentially increase your customer base and revenue, depending on demand for these treatments.

If you are a retiree

As a retiree, you may rely on compounded medications for managing chronic health issues. The addition of peptides to the compounding list could provide you with more treatment options, but it may also raise concerns about the safety and regulation of these new substances.

What does this mean for YOU, specifically?

Ripple builds a profile of your life — your career, your city, your family — and tells you how each story hits it. The analysis above is generic; yours won't be.

Get your Ripple